Welcome, Lara Meisner! With 25 years of #biopharma experience, Lara brings a track record of building and leading legal functions at public #biotech companies, advising on capital markets, governance, compliance and more. We look forward to her contributions at CellCentric.

Updated Phase 2 data at #EHA2026! Next week in Stockholm, we are excited to be presenting updated results from our randomized Phase 2 dose optimization study of inobrodib + pom/dex (InoPd) in relapsed/refractory #multiplemyeloma. Visit us at Booth # H2.03!

We’re excited to announce the launch of mminovation.com, a new resource for U.S. HCPs. Explore the science behind inobrodib's novel mechanism of action, learn about ongoing clinical trials, and hear from the MM community.

CellCentric looks forward to engaging with the #oncology community at #ASCO26 as we share ongoing progress in the development of inobrodib, our first-in-class investigational oral p300/CBP inhibitor for #multiplemyeloma. See you in Chicago!

We’ve closed an oversubscribed $220M Series D financing to advance pivotal trials of inobrodib in #multiplemyeloma. Led by @Venrock, this funding reflects strong conviction in inobrodib’s potential to address a critical need after BCMA/TCE therapies. More: cellcentric.com/press-releas…

Inobrodib is a first-in-class oral therapy designed to target p300/CBP - proteins that play an important role in driving #multiplemyeloma. By binding to and displacing p300/CBP, inobrodib reduces the expression of key cancer drivers MYC and IRF4.

By approaching the same pathway through distinct mechanisms, the combo of ino+pom has potential to drive meaningful responses in #MM, supporting our focus on advancing a novel oral treatment option, particularly for those who have already had an antibody-based therapy (BCMA/TCE).

Last month, our transatlantic team took part in the Walk of Light Step Challenge, organized by @bloodcancer_uk. Together, we took more than 11 million steps, surpassing the amount of steps between our UK/US offices, while helping raise awareness of blood cancers, including MM.

We’re excited to announce the initiation of DOMMINO-1, our pivotal Phase 2 trial of inobrodib + pom + dex (InoPd) in relapsed/refractory multiple myeloma. The first patient has been dosed, and enrollment is underway across the UK and US. Details: cellcentric.com/press-releas…

Majority of heavily pretreated relapsed/refractory #MM patients receive care in community settings. Inobrodib is our investigational oral drug + novel MoA. Delivered with pom/dex, we aim to address an unmet need for people who relapsed or weren’t eligible for TCE/BCMA agents.

We strive to maintain a workplace where we show up for one another & the people with cancer we aim to serve. On #EmployeeAppreciationDay, we celebrate our team. Together, we move toward our shared vision to improve the lives of those with cancer. Join us: cellcentric.com/careers

MM is a complex blood cancer that remains incurable for many. On #RareDiseaseDay, we recognize the individuals, families and communities impacted and the ongoing need for better, longer-lasting treatment options. We’re proud to be working to reshape care for rare cancers like MM.

CellCentric is headed to 📍Boston next week! We look forward to connecting with the investor community to share our progress advancing inobrodib, our first-in-class investigational oral therapy for the treatment of #multiplemyeloma.

Inobrodib is our investigational oral drug with a novel MoA. Delivered as a capsule, and used as part of an all-oral regimen with pom/dex (InoPd) for later line patients, it suits community-based care + may improve access for those with later stage #MM. Pivotal studies this year.

We have a deep appreciation for the women in STEM who drive innovation forward. On #IDWGS, we’re proud to recognize the women at CellCentric whose expertise, collaboration and commitment help advance science for people living with #multiplemyeloma. Learn more below. #WomeninSTEM

Every person’s experience with cancer is unique. That belief drives our people-centered approach: listening, understanding the needs of those impacted by #cancer and advancing innovation for communities with significant unmet need, including #MM. #WorldCancerDay #UnitedByUnique

CellCentric is headed to San Francisco for #JPM26! We look forward to connecting with the healthcare community and partners who share our vision for addressing unmet needs in #multiplemyeloma through novel, differentiated innovation. See you there!

As an all-oral regimen, InoPd has potential to enhance how #MM is managed in the community setting, where 70%+ of patients are treated. A well-tolerated and accessible treatment option, we believe InoPd could transform care for patients after, or instead of, BCMA/TCE agents.

New Phase 2 data at #ASH25 from our investigational, all-oral therapy InoPd (inobrodib + pom/dex) show promising clinical efficacy & tolerable safety profile in heavily pretreated patients with relapsed/refractory #MM. Initial positioning, after bispi. cellcentric.com/press-releas…

Many #MM patients either are ineligible for a bispecific or cannot tolerate the treatment within the first few months. More to come @ #ASH25 from our Phase 2 expansion arm data of InoPd, with potential to address a major unmet need in the post-BCMA/TCE therapy patient population.